CANCER THERAPY BY INTRATUMORAL INJECTION OF A CHEMOTHERAPEUTIC AGENT IN COMBINATION WITH A BIOACTIVE IMMUNOSTIMULATORY AGENT

SYBLEU, Inc. (OTC PINK: SYBE) is a biotechnology company focused on therapies for human and animal health, medical devices, and clinical diagnostics. We actively pursue strategic acquisitions and in-licensing opportunities to expand our intellectual property portfolio and seek to form strategic partnerships to bring these technologies to market.